This will now take at least 3 years to get to market. I am not sure they will make the journey with the current board. All should be immediately removed and replaced. Actions will speak louder than words and it is time the major shareholders stood up. To let Mercer and Clarke drive this opportunity into the dirt, is, if not a crime, then is certainly morally reprehensible. I will be writing to the CEO to ask if the UK and by default BSI leave the EU later this year (which is probable) then what will be the outcome of the trial if BSI are no longer recognised by the EU? What is the point in sticking with BSI or the EU. Based on the info supplied, I will hope that the same due diligence KNOW being conducted for the EU regulators has also been done for the FDA. If the FDA approval is of a similar duration to the new EU trial then they should dump the EU immediately and go for the FDA approval. In 3 years there might be a total reset of the EU if Greece and the UK exit.
My greatest fear is that in 3 years the product will be redundant as other products will be brought to market and TIS will have missed one of the greatest opportunities in recent memory. Putting this company on your CV will be the kiss of death for anyone.
TIS Price at posting:
5.0¢ Sentiment: Hold Disclosure: Held
